Difference between revisions of "Mitoxantrone (Novantrone)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf Mitoxantrone (Novantrone) package inse...") |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf Mitoxantrone (Novantrone) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/mitoxantrone.pdf Mitoxantrone (Novantrone) package insert (locally hosted backup)]</ref> | + | Class/mechanism: Synthetic antineoplastic anthracenedione, intercalates into DNA, causing crosslinking and strand breaks. Mitoxantrone inhibits topoisomerase II, which helps to uncoil and repair damaged DNA. It also has been observed to interfere with RNA and has activity against resting and proliferating cells. In vitro, it has been observed to interfere with antigen presentation; inhibit B-cell, T-cell, and macrophage proliferation; and decrease secretion of interferon gamma, tumor necrosis factor-alpha (TNF-α), and interleukin-2 (IL-2).<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf Mitoxantrone (Novantrone) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/mitoxantrone.pdf Mitoxantrone (Novantrone) package insert (locally hosted backup)]</ref> |
| − | <br>Route: | + | <br>Route: IV |
| − | <br>Extravasation: | + | <br>Extravasation: [[irritant]] (usually), [[vesicant]] (rare) |
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | ||
==Patient drug information== | ==Patient drug information== | ||
| + | *[http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf#page=36 Mitoxantrone (Novantrone) package insert PDF page 36-41]<ref name="insert"></ref> | ||
*[http://chemocare.com/bio/mitoxantrone.asp Mitoxantrone (Novantrone) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/mitoxantrone.asp Mitoxantrone (Novantrone) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/mitoxantrone.asp Mitoxantrone (Novantrone) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/mitoxantrone.asp Mitoxantrone (Novantrone) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/mitoxantrone-patient-drug-information Mitoxantrone (Novantrone) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/mitoxantrone-patient-drug-information Mitoxantrone (Novantrone) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/mitoxantrone-patient-drug-information Mitoxantrone (Novantrone) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/mitoxantrone-patient-drug-information Mitoxantrone (Novantrone) patient drug information (UpToDate)]</ref> | ||
Revision as of 20:31, 23 February 2012
General information
Class/mechanism: Synthetic antineoplastic anthracenedione, intercalates into DNA, causing crosslinking and strand breaks. Mitoxantrone inhibits topoisomerase II, which helps to uncoil and repair damaged DNA. It also has been observed to interfere with RNA and has activity against resting and proliferating cells. In vitro, it has been observed to interfere with antigen presentation; inhibit B-cell, T-cell, and macrophage proliferation; and decrease secretion of interferon gamma, tumor necrosis factor-alpha (TNF-α), and interleukin-2 (IL-2).[1][2]
Route: IV
Extravasation: irritant (usually), vesicant (rare)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Mitoxantrone (Novantrone) package insert PDF page 36-41[1]
- Mitoxantrone (Novantrone) patient drug information (Chemocare)[3]
- Mitoxantrone (Novantrone) patient drug information (UpToDate)[4]